16727-47-2

Basic information

• Product Name: 2,6-Bis(benzyloxy)-3-bromopyridine
• Synonyms: 2,6-Bis(benzyloxy)-3-bromopyridine
• CAS NO: 16727-47-2
• Molecular Formula: C₁₉H₁₆BrNO₂
• Molecular Weight: 370
• Mol File: 16727-47-2.mol

Chemical Properties

• Boiling Point: 455.4±40.0 °C(Predicted)
• Appearance: /
• Density: 1.380±0.06 g/cm3(Predicted)
• Storage Temp.: Room temperature.
• PKA: 0.22±0.34(Predicted)
• CAS DataBase Reference: 2,6-Bis(benzyloxy)-3-bromopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Bis(benzyloxy)-3-bromopyridine(16727-47-2)
• EPA Substance Registry System: 2,6-Bis(benzyloxy)-3-bromopyridine(16727-47-2)

Safety Data

• Hazardous Substances Data: 16727-47-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
2,6-Bis(benzyloxy)-3-bromopyridine is used as a reagent for studying bacterial oxidation of nicotine. Its application in this field is significant as it aids in understanding the metabolic pathways and enzymatic processes involved in nicotine degradation, which can be crucial for developing new strategies to combat nicotine addiction and related health issues.
Used in Chemical Synthesis:
In the field of chemical synthesis, 2,6-Bis(benzyloxy)-3-bromopyridine can be utilized as a building block or intermediate for the development of more complex molecules with potential applications in various industries, such as pharmaceuticals, agrochemicals, and materials science. Its unique structure allows for further functionalization and modification, making it a valuable compound for synthetic chemists.
Used in Analytical Chemistry:
2,6-Bis(benzyloxy)-3-bromopyridine can also be employed in analytical chemistry as a reference compound or standard for the development and validation of analytical methods, such as high-performance liquid chromatography (HPLC), gas chromatography (GC), and mass spectrometry (MS). Its distinct chemical properties and structural features make it suitable for these purposes, contributing to the advancement of analytical techniques and methodologies.

Upstream product

• 80392-79-6 3-bromo-2,6-difluoro-pyridine 
• 100-51-6 benzyl alcohol 
• 2402-78-0 2,6-dichloropyridine 
• 16727-46-1 2,6-bis(benzyloxy)pyridine 

Downstream Products

• 39954-16-0 2,6-dibenzyloxypyridin-3-ol 

Relevant articles and documents

CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are piperidine dione compounds having the following structure: wherein R1, R2, R3, R4, L, V, X, a and m are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF

Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer 5 or a metabolic disease.

BRAF DEGRADERS

Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.

BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER

The invention provides bifunctional compounds of formula (I) or a pharmaceutically acceptable salt thereof. Formula (I). The compounds cause the degradation of SMARCA2 via the targeted ubiquination of SMARCA2 protein and subsequent proteasomal degradation and are thus useful for the treatment of cancer. The targeting ligand is of formula (TL).

N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION

This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.